HomeNew Ras Inhibitors

New Ras Inhibitors

Catalog No. Product Name Information
E5848 ERAS-0015 ERAS-0015(JYP0015) is a tricomplex inhibitor of panRAS(ON) targeting of active RAS, it binds to Cyclophilin A (CYPA) to form a high-affinity complex that sterically occludes RAS–effector interactions. It exhibits potential for research in RAS-mutant solid tumors.
E1959 RMC-4998 RMC-4998 is a tri-complex inhibitor that selectively targets the GTP-bound state of mutant KRASG12C, with high potency for KRASG12C-CYPA tri-complex formation with an IC50 of 28 nM. It strongly inhibits ERK signaling with an IC50 of 1–10 nM and attenuates AKT/MTOR and RAL pathways, leading to potent suppression of KRASG12C-driven tumor growth and can used in cancer research.
E1843 Fulzerasib Fulzerasib (IBI351, GFH925) is an irreversible small molecule inhibitor for KRAS G12C mutation blocking KRAS pathway signaling pERK with an IC50 of 37 nM. It demonstrates potent anti-tumor activity in multiple KRAS G12C-mutant tumor models including human pancreatic cancer, human lung adenocarcinoma, colorectal adenocarcinoma, and lung cancer models.
E1677 Glecirasib Glecirasib (JAB-21822, KRAS G12C inhibitor 36) is a potent, and highly selective, covalent inhibitor of KRAS G12C. It exhibits promising anti-tumor activity in KRAS G12C-mutated pancreatic ductal adenocarcinoma (PDAC) , Non-Small Cell Lung Cancer(NSCLC), Colorectal Cancer (CRC) and other solid tumors.
E1856 ARS-1323 ARS-1323 is the racemic mixture, containing ARS-1620, and a potent inhibitor of mutant KRAS G12C. It can be used in research for biochemical binding screens as companion imaging drugs (CID) for KRAS G12C.
≡ All Ras Inhibitors